Isomorphic Labs raises $5 billion in second mega-round in six months
Original title: Isomorphic Labs raises $5 billion in its second mega-round within six months
The May 2026 round was $2.1 billion; funds target IsoDDE and clinical trials, with no approved drug yet.
Alphabet’s drug-discovery company Isomorphic Labs raised $5 billion, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz, Alphabet and existing investors. The company says the money will advance its IsoDDE platform, which it says goes beyond AlphaFold 3 on binding and docking, and move its pipeline toward trials. It works with Novartis, Eli Lilly and Johnson & Johnson. Demis Hassabis leads the firm after leaving day-to-day Google DeepMind leadership in August 2026.
Unconfirmed: Claims that IsoDDE predicts binding and docking better than AlphaFold 3 are the company’s.
- Isomorphic Labs was founded in 2021 and is led by Demis Hassabis.
- DeepMind’s original AlphaFold team was disbanded in July 2026.
- Nearly a quarter of that team left DeepMind; many joined Isomorphic or other projects.
- DeepMind shipped AlphaGenome 2 in early November 2026.
- Vendors
- Alphabet
- Products
- IsoDDE
- Organizations
- Isomorphic LabsGreenoaksSequoia CapitalAndreessen HorowitzNovartisEli LillyJohnson & JohnsonGoogle DeepMind
- AI models
- AlphaFold 3AlphaGenome 2
From the original article
1 min read at the-decoder.com
Isomorphic Labs has raised $5 billion, just six months after a $2. 1 billion round. Alphabet's AI drug discovery company, led by Demis Hassabis, plans to use the funding to push its drug pipeline toward clinical trials.
By Maximilian Schreiner · the-decoder.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.